Optimer (OPTR) Announces Add-on Payment From Medicare & Medicaid Services for its DIFICID
- Wall Street indexes flat in pre-holiday lull; health, consumer up
- Market Wrap: Durable Orders Outpace in Oct.; Deere Issues Cautious Outlook; Valeant Combats Short Sellers
- UPDATE: HP, Inc. (HPQ) Misses Q4 EPS by 3c; Issues Q1, FY16 EPS Guidance
- Obama says U.S. is safe as millions set off on Thanksgiving travel
- Deere & Co. (DE) Tops Q4 EPS Views; Sees FY16 Sales Down ~7%
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for DIFICID tablets administered in the inpatient setting to treat Clostridium difficile-associated diarrhea (CDAD). Introduced in 2001, the CMS NTAP program is designed to support timely access of innovative therapies used to treat Medicare beneficiaries in the inpatient setting. The NTAP program is only available to new technologies demonstrating a substantial clinical improvement and meeting specific cost thresholds. The NTAP payment will provide hospitals with a payment, in addition to the standard-of-care DRG reimbursement, of up to 50% of the cost of DIFICID for a period of two to three years, effective in the fiscal year starting on October 1, 2012. For 2013, CMS has assigned a maximum payment of $868.00. The NTAP payment is available to hospitals only for individual patient cases that are more costly than the average DRG charges.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Spectrum Pharma (SPPI) Says FDA Set Target Decision Date of May 9 for EVOMELA NDA
- Cigna Corp. (CI) Enters Settlement with Anthem (ANTM)
- Amgen (AMGN) Submits ABP 501 BLA to FDA
Create E-mail Alert Related CategoriesCorporate News, FDA
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!